和鉑醫藥-B(02142.HK):預計中期溢利100萬美元至150萬美元
格隆匯7月19日丨和鉑醫藥-B(02142.HK)發佈公吿,截至2024年6月30日止六個月(“報吿期間”),預期集團於報吿期間的溢利將介乎100萬美元至150萬美元,而截至2023年6月30日止六個月(“2023年上半年”)的溢利約為290萬美元。於報吿期間,預期溢利減少主要由於收入結構變動所致。尤其是,報吿期間來自服務業務的收費佔總收入的比例較2023年上半年的收入有所增加。然而,相較於2023年上半年收入中佔較大比例的授權收入,此類收入的利潤率相對較薄。因此,報吿期間的整體溢利有所減少。
儘管預期報吿期間的溢利較2023年上半年有所減少,但公司強調,鑑於(i)公司擁有穩定的收入來源及多元化的收入結構,於報吿期間的付款中,公司從其現有管線中已實現授權及合作的創新項目中獲得里程碑付款(“授權及合作”),這對報吿期間的收入做出了重大貢獻;(ii)於2024年,公司加快其業務拓展,於報吿期間訂立的新授權及合作(例如於2024年5月的臨牀前資產合作)帶動集團經營業績持續增長,突顯了將公司業務合作伙伴的見解與公司世界一流的抗體發現專長相協同的發展潛力;及(iii)加強集團業務營運成本控制的一貫策略,故預期報吿期間將維持整體溢利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.